Ontology type: schema:ScholarlyArticle Open Access: True
2021-02-07
AUTHORSGian Paolo Fadini, Olga Disoteo, Riccardo Candido, Paolo Di Bartolo, Luigi Laviola, Agostino Consoli
ABSTRACTIntroductionThe aim of this study was to elaborate a consensus on treatment intensification strategies in patients with type 2 diabetes failing basal insulin supported oral therapy (BOT). The panel focused on glucagon-like peptide-1 receptor agonists (GLP-1RA) and basal insulin (BI) combinations.MethodsThe authors developed a Delphi questionnaire organized into ten statements and 77 items that focused on: the definition of BOT and BOT failure, intensification strategies, fixed-dose combinations in general and the BI/GLP-1RA fixed combination. The survey was administered in two rounds to a panel of 80 Italian diabetes specialists, who rated their level of agreement with each item on a 5-point Likert scale. Consensus was predefined as > 66% of the panel agreeing/disagreeing on any given item.ResultsConsensus was achieved for 71 of the 77 items. The panel agreed that the use of sulfonylureas in the BOT regimen is inappropriate. BOT failure was defined as individualized targets not being met for glycated hemoglobin, fasting plasma glucose and/or postprandial plasma glucose. There was agreement that postprandial hyperglycaemia and/or presence of nocturnal hypoglycaemia or weight gain define BOT failure. Addition of a GLP-1RA to BI therapy was considered to be the best option for BOT intensification. There was consensus for the use of BI/GLP-1RA fixed combinations as valuable options to increase compliance and safely improve glycaemic control. The panel agreed in considering the fixed-ratio combination insulin degludec/liraglutide (IDegLira) to be preferable to the fixed-ratio combination insulin glargine/lixisenatide (iGlarLixi) in the control of glycaemia, body weight and cardiovascular risk.ConclusionAccording to this Delphi consensus, the addition of a GLP-1RA may be the best option to intensify BOT. The BI/GLP-1RA fixed combinations may increase compliance and optimize the advantages of each of these molecules. More... »
PAGES781-800
http://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2
DOIhttp://dx.doi.org/10.1007/s13300-021-01012-2
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1135197350
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/33550569
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Division of Metabolic Diseases, Department of Medicine, University of Padova, Padua, Italy",
"id": "http://www.grid.ac/institutes/grid.5608.b",
"name": [
"Division of Metabolic Diseases, Department of Medicine, University of Padova, Padua, Italy"
],
"type": "Organization"
},
"familyName": "Fadini",
"givenName": "Gian Paolo",
"id": "sg:person.01122137075.78",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122137075.78"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Diabetes Unit, SSD Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Diabetes Unit, SSD Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"
],
"type": "Organization"
},
"familyName": "Disoteo",
"givenName": "Olga",
"id": "sg:person.010554524053.41",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010554524053.41"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Diabetes Center District 3, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Diabetes Center District 3, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy"
],
"type": "Organization"
},
"familyName": "Candido",
"givenName": "Riccardo",
"id": "sg:person.01026702544.26",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ravenna Diabetes Clinic, Romagna Local Health Authority, Ravenna, Italy",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Ravenna Diabetes Clinic, Romagna Local Health Authority, Ravenna, Italy"
],
"type": "Organization"
},
"familyName": "Di Bartolo",
"givenName": "Paolo",
"id": "sg:person.0706015255.97",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706015255.97"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Transplants, University of Bari Aldo Moro, Bari, Italy",
"id": "http://www.grid.ac/institutes/grid.7644.1",
"name": [
"Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Transplants, University of Bari Aldo Moro, Bari, Italy"
],
"type": "Organization"
},
"familyName": "Laviola",
"givenName": "Luigi",
"id": "sg:person.01354727540.43",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354727540.43"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine and Aging Sciences (DMSI) and Center for Research on Ageing and Translational Medicine (CeSI-Met), University of Chieti, Chieti, Italy",
"id": "http://www.grid.ac/institutes/grid.412451.7",
"name": [
"Department of Medicine and Aging Sciences (DMSI) and Center for Research on Ageing and Translational Medicine (CeSI-Met), University of Chieti, Chieti, Italy"
],
"type": "Organization"
},
"familyName": "Consoli",
"givenName": "Agostino",
"id": "sg:person.01117461427.40",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117461427.40"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s12325-018-0868-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1111099911",
"https://doi.org/10.1007/s12325-018-0868-9"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s13300-019-00715-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1122193928",
"https://doi.org/10.1007/s13300-019-00715-x"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s13300-019-00735-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1123468257",
"https://doi.org/10.1007/s13300-019-00735-7"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s13300-018-0452-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1104347182",
"https://doi.org/10.1007/s13300-018-0452-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s13300-019-0624-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1113668568",
"https://doi.org/10.1007/s13300-019-0624-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s13300-015-0142-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1048653953",
"https://doi.org/10.1007/s13300-015-0142-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s13300-019-00725-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1123157757",
"https://doi.org/10.1007/s13300-019-00725-9"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-02-07",
"datePublishedReg": "2021-02-07",
"description": "IntroductionThe aim of this study was to elaborate a consensus on treatment intensification strategies in patients with type 2 diabetes failing basal insulin supported oral therapy (BOT). The panel focused on glucagon-like peptide-1 receptor agonists (GLP-1RA) and basal insulin (BI) combinations.MethodsThe authors developed a Delphi questionnaire organized into ten statements and 77 items that focused on: the definition of BOT and BOT failure, intensification strategies, fixed-dose combinations in general and the BI/GLP-1RA fixed combination. The survey was administered in two rounds to a panel of 80 Italian diabetes specialists, who rated their level of agreement with each item on a 5-point Likert scale. Consensus was predefined as >\u200966% of the panel agreeing/disagreeing on any given item.ResultsConsensus was achieved for 71 of the 77 items. The panel agreed that the use of sulfonylureas in the BOT regimen is inappropriate. BOT failure was defined as individualized targets not being met for glycated hemoglobin, fasting plasma glucose and/or postprandial plasma glucose. There was agreement that postprandial hyperglycaemia and/or presence of nocturnal hypoglycaemia or weight gain define BOT failure. Addition of a GLP-1RA to BI therapy was considered to be the best option for BOT intensification. There was consensus for the use of BI/GLP-1RA fixed combinations as valuable options to increase compliance and safely improve glycaemic control. The panel agreed in considering the fixed-ratio combination insulin degludec/liraglutide (IDegLira) to be preferable to the fixed-ratio combination insulin glargine/lixisenatide (iGlarLixi) in the control of glycaemia, body weight and cardiovascular risk.ConclusionAccording to this Delphi consensus, the addition of a GLP-1RA may be the best option to intensify BOT. The BI/GLP-1RA fixed combinations may increase compliance and optimize the advantages of each of these molecules.",
"genre": "article",
"id": "sg:pub.10.1007/s13300-021-01012-2",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1044057",
"issn": [
"1869-6953",
"1869-6961"
],
"name": "Diabetes Therapy",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "3",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "12"
}
],
"keywords": [
"GLP-1RAs",
"basal insulin",
"plasma glucose",
"glucagon-like peptide-1 receptor agonists",
"insulin glargine/lixisenatide",
"peptide-1 receptor agonists",
"insulin degludec/liraglutide",
"agonist combination therapy",
"degludec/liraglutide",
"postprandial plasma glucose",
"treatment intensification strategies",
"use of sulfonylureas",
"fixed-dose combination",
"type 2 diabetes",
"control of glycaemia",
"insulin combinations",
"treatment intensification",
"oral therapy",
"nocturnal hypoglycaemia",
"glycaemic control",
"cardiovascular risk",
"postprandial hyperglycaemia",
"oral treatment",
"diabetes specialists",
"BI therapy",
"combination therapy",
"glycated hemoglobin",
"receptor agonist",
"IntroductionThe aim",
"Delphi consensus",
"body weight",
"type 2",
"level of agreement",
"MethodsThe authors",
"therapy",
"valuable option",
"insulin",
"best option",
"Delphi questionnaire",
"Likert scale",
"failure",
"glucose",
"options",
"lixisenatide",
"liraglutide",
"hyperglycaemia",
"hypoglycaemia",
"ResultsConsensus",
"regimen",
"glycaemia",
"patients",
"diabetes",
"consensus",
"compliance",
"agonists",
"sulfonylureas",
"hemoglobin",
"treatment",
"panel",
"risk",
"control",
"intensification strategies",
"questionnaire",
"subjects",
"GLP",
"combination",
"items",
"aim",
"use",
"specialists",
"target",
"levels",
"addition",
"weight",
"strategies",
"study",
"survey",
"presence",
"rounds",
"scale",
"Delphi",
"authors",
"statements",
"molecules",
"definition",
"disagreeing",
"intensification",
"advantages",
"agreement",
"bots"
],
"name": "Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies",
"pagination": "781-800",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1135197350"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s13300-021-01012-2"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"33550569"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s13300-021-01012-2",
"https://app.dimensions.ai/details/publication/pub.1135197350"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:29",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_913.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s13300-021-01012-2"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-021-01012-2'
This table displays all metadata directly associated to this object as RDF triples.
228 TRIPLES
22 PREDICATES
123 URIs
108 LITERALS
7 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s13300-021-01012-2 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1103 |
3 | ″ | schema:author | Ne9ffc075462f451597e3c9e7d5d8c7e5 |
4 | ″ | schema:citation | sg:pub.10.1007/s12325-018-0868-9 |
5 | ″ | ″ | sg:pub.10.1007/s13300-015-0142-y |
6 | ″ | ″ | sg:pub.10.1007/s13300-018-0452-y |
7 | ″ | ″ | sg:pub.10.1007/s13300-019-00715-x |
8 | ″ | ″ | sg:pub.10.1007/s13300-019-00725-9 |
9 | ″ | ″ | sg:pub.10.1007/s13300-019-00735-7 |
10 | ″ | ″ | sg:pub.10.1007/s13300-019-0624-4 |
11 | ″ | schema:datePublished | 2021-02-07 |
12 | ″ | schema:datePublishedReg | 2021-02-07 |
13 | ″ | schema:description | IntroductionThe aim of this study was to elaborate a consensus on treatment intensification strategies in patients with type 2 diabetes failing basal insulin supported oral therapy (BOT). The panel focused on glucagon-like peptide-1 receptor agonists (GLP-1RA) and basal insulin (BI) combinations.MethodsThe authors developed a Delphi questionnaire organized into ten statements and 77 items that focused on: the definition of BOT and BOT failure, intensification strategies, fixed-dose combinations in general and the BI/GLP-1RA fixed combination. The survey was administered in two rounds to a panel of 80 Italian diabetes specialists, who rated their level of agreement with each item on a 5-point Likert scale. Consensus was predefined as > 66% of the panel agreeing/disagreeing on any given item.ResultsConsensus was achieved for 71 of the 77 items. The panel agreed that the use of sulfonylureas in the BOT regimen is inappropriate. BOT failure was defined as individualized targets not being met for glycated hemoglobin, fasting plasma glucose and/or postprandial plasma glucose. There was agreement that postprandial hyperglycaemia and/or presence of nocturnal hypoglycaemia or weight gain define BOT failure. Addition of a GLP-1RA to BI therapy was considered to be the best option for BOT intensification. There was consensus for the use of BI/GLP-1RA fixed combinations as valuable options to increase compliance and safely improve glycaemic control. The panel agreed in considering the fixed-ratio combination insulin degludec/liraglutide (IDegLira) to be preferable to the fixed-ratio combination insulin glargine/lixisenatide (iGlarLixi) in the control of glycaemia, body weight and cardiovascular risk.ConclusionAccording to this Delphi consensus, the addition of a GLP-1RA may be the best option to intensify BOT. The BI/GLP-1RA fixed combinations may increase compliance and optimize the advantages of each of these molecules. |
14 | ″ | schema:genre | article |
15 | ″ | schema:inLanguage | en |
16 | ″ | schema:isAccessibleForFree | true |
17 | ″ | schema:isPartOf | N12b1ea8382244314a4f214beda2afe1d |
18 | ″ | ″ | N5497f9079419443dbd880a36ae6f2be1 |
19 | ″ | ″ | sg:journal.1044057 |
20 | ″ | schema:keywords | BI therapy |
21 | ″ | ″ | Delphi |
22 | ″ | ″ | Delphi consensus |
23 | ″ | ″ | Delphi questionnaire |
24 | ″ | ″ | GLP |
25 | ″ | ″ | GLP-1RAs |
26 | ″ | ″ | IntroductionThe aim |
27 | ″ | ″ | Likert scale |
28 | ″ | ″ | MethodsThe authors |
29 | ″ | ″ | ResultsConsensus |
30 | ″ | ″ | addition |
31 | ″ | ″ | advantages |
32 | ″ | ″ | agonist combination therapy |
33 | ″ | ″ | agonists |
34 | ″ | ″ | agreement |
35 | ″ | ″ | aim |
36 | ″ | ″ | authors |
37 | ″ | ″ | basal insulin |
38 | ″ | ″ | best option |
39 | ″ | ″ | body weight |
40 | ″ | ″ | bots |
41 | ″ | ″ | cardiovascular risk |
42 | ″ | ″ | combination |
43 | ″ | ″ | combination therapy |
44 | ″ | ″ | compliance |
45 | ″ | ″ | consensus |
46 | ″ | ″ | control |
47 | ″ | ″ | control of glycaemia |
48 | ″ | ″ | definition |
49 | ″ | ″ | degludec/liraglutide |
50 | ″ | ″ | diabetes |
51 | ″ | ″ | diabetes specialists |
52 | ″ | ″ | disagreeing |
53 | ″ | ″ | failure |
54 | ″ | ″ | fixed-dose combination |
55 | ″ | ″ | glucagon-like peptide-1 receptor agonists |
56 | ″ | ″ | glucose |
57 | ″ | ″ | glycaemia |
58 | ″ | ″ | glycaemic control |
59 | ″ | ″ | glycated hemoglobin |
60 | ″ | ″ | hemoglobin |
61 | ″ | ″ | hyperglycaemia |
62 | ″ | ″ | hypoglycaemia |
63 | ″ | ″ | insulin |
64 | ″ | ″ | insulin combinations |
65 | ″ | ″ | insulin degludec/liraglutide |
66 | ″ | ″ | insulin glargine/lixisenatide |
67 | ″ | ″ | intensification |
68 | ″ | ″ | intensification strategies |
69 | ″ | ″ | items |
70 | ″ | ″ | level of agreement |
71 | ″ | ″ | levels |
72 | ″ | ″ | liraglutide |
73 | ″ | ″ | lixisenatide |
74 | ″ | ″ | molecules |
75 | ″ | ″ | nocturnal hypoglycaemia |
76 | ″ | ″ | options |
77 | ″ | ″ | oral therapy |
78 | ″ | ″ | oral treatment |
79 | ″ | ″ | panel |
80 | ″ | ″ | patients |
81 | ″ | ″ | peptide-1 receptor agonists |
82 | ″ | ″ | plasma glucose |
83 | ″ | ″ | postprandial hyperglycaemia |
84 | ″ | ″ | postprandial plasma glucose |
85 | ″ | ″ | presence |
86 | ″ | ″ | questionnaire |
87 | ″ | ″ | receptor agonist |
88 | ″ | ″ | regimen |
89 | ″ | ″ | risk |
90 | ″ | ″ | rounds |
91 | ″ | ″ | scale |
92 | ″ | ″ | specialists |
93 | ″ | ″ | statements |
94 | ″ | ″ | strategies |
95 | ″ | ″ | study |
96 | ″ | ″ | subjects |
97 | ″ | ″ | sulfonylureas |
98 | ″ | ″ | survey |
99 | ″ | ″ | target |
100 | ″ | ″ | therapy |
101 | ″ | ″ | treatment |
102 | ″ | ″ | treatment intensification |
103 | ″ | ″ | treatment intensification strategies |
104 | ″ | ″ | type 2 |
105 | ″ | ″ | type 2 diabetes |
106 | ″ | ″ | use |
107 | ″ | ″ | use of sulfonylureas |
108 | ″ | ″ | valuable option |
109 | ″ | ″ | weight |
110 | ″ | schema:name | Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies |
111 | ″ | schema:pagination | 781-800 |
112 | ″ | schema:productId | N99f6747d754d444c957b65d7f75b9045 |
113 | ″ | ″ | Nb180ad2162eb4ad996d9bc50eb907c03 |
114 | ″ | ″ | Nf3e8b1274efd4095b0fa4cdb51619bab |
115 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1135197350 |
116 | ″ | ″ | https://doi.org/10.1007/s13300-021-01012-2 |
117 | ″ | schema:sdDatePublished | 2022-05-10T10:29 |
118 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
119 | ″ | schema:sdPublisher | Nef6e3f7e40c0488eb0c15866defc4376 |
120 | ″ | schema:url | https://doi.org/10.1007/s13300-021-01012-2 |
121 | ″ | sgo:license | sg:explorer/license/ |
122 | ″ | sgo:sdDataset | articles |
123 | ″ | rdf:type | schema:ScholarlyArticle |
124 | N12b1ea8382244314a4f214beda2afe1d | schema:volumeNumber | 12 |
125 | ″ | rdf:type | schema:PublicationVolume |
126 | N2d346c84e32e482a87cfdac0189bca53 | rdf:first | sg:person.01026702544.26 |
127 | ″ | rdf:rest | N8597591a7f2945a3a99023482cd14ac8 |
128 | N5497f9079419443dbd880a36ae6f2be1 | schema:issueNumber | 3 |
129 | ″ | rdf:type | schema:PublicationIssue |
130 | N84f60047e6d6494f80ad7f5519b8746c | rdf:first | sg:person.010554524053.41 |
131 | ″ | rdf:rest | N2d346c84e32e482a87cfdac0189bca53 |
132 | N8597591a7f2945a3a99023482cd14ac8 | rdf:first | sg:person.0706015255.97 |
133 | ″ | rdf:rest | Nefede7b034fd48c8ab0c47f6a1b9ac59 |
134 | N8925ba6b822f4c4e965b3ffd479afb6a | rdf:first | sg:person.01117461427.40 |
135 | ″ | rdf:rest | rdf:nil |
136 | N99f6747d754d444c957b65d7f75b9045 | schema:name | dimensions_id |
137 | ″ | schema:value | pub.1135197350 |
138 | ″ | rdf:type | schema:PropertyValue |
139 | Nb180ad2162eb4ad996d9bc50eb907c03 | schema:name | doi |
140 | ″ | schema:value | 10.1007/s13300-021-01012-2 |
141 | ″ | rdf:type | schema:PropertyValue |
142 | Ne9ffc075462f451597e3c9e7d5d8c7e5 | rdf:first | sg:person.01122137075.78 |
143 | ″ | rdf:rest | N84f60047e6d6494f80ad7f5519b8746c |
144 | Nef6e3f7e40c0488eb0c15866defc4376 | schema:name | Springer Nature - SN SciGraph project |
145 | ″ | rdf:type | schema:Organization |
146 | Nefede7b034fd48c8ab0c47f6a1b9ac59 | rdf:first | sg:person.01354727540.43 |
147 | ″ | rdf:rest | N8925ba6b822f4c4e965b3ffd479afb6a |
148 | Nf3e8b1274efd4095b0fa4cdb51619bab | schema:name | pubmed_id |
149 | ″ | schema:value | 33550569 |
150 | ″ | rdf:type | schema:PropertyValue |
151 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
152 | ″ | schema:name | Medical and Health Sciences |
153 | ″ | rdf:type | schema:DefinedTerm |
154 | anzsrc-for:1103 | schema:inDefinedTermSet | anzsrc-for: |
155 | ″ | schema:name | Clinical Sciences |
156 | ″ | rdf:type | schema:DefinedTerm |
157 | sg:journal.1044057 | schema:issn | 1869-6953 |
158 | ″ | ″ | 1869-6961 |
159 | ″ | schema:name | Diabetes Therapy |
160 | ″ | schema:publisher | Springer Nature |
161 | ″ | rdf:type | schema:Periodical |
162 | sg:person.01026702544.26 | schema:affiliation | grid-institutes:None |
163 | ″ | schema:familyName | Candido |
164 | ″ | schema:givenName | Riccardo |
165 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26 |
166 | ″ | rdf:type | schema:Person |
167 | sg:person.010554524053.41 | schema:affiliation | grid-institutes:None |
168 | ″ | schema:familyName | Disoteo |
169 | ″ | schema:givenName | Olga |
170 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010554524053.41 |
171 | ″ | rdf:type | schema:Person |
172 | sg:person.01117461427.40 | schema:affiliation | grid-institutes:grid.412451.7 |
173 | ″ | schema:familyName | Consoli |
174 | ″ | schema:givenName | Agostino |
175 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117461427.40 |
176 | ″ | rdf:type | schema:Person |
177 | sg:person.01122137075.78 | schema:affiliation | grid-institutes:grid.5608.b |
178 | ″ | schema:familyName | Fadini |
179 | ″ | schema:givenName | Gian Paolo |
180 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122137075.78 |
181 | ″ | rdf:type | schema:Person |
182 | sg:person.01354727540.43 | schema:affiliation | grid-institutes:grid.7644.1 |
183 | ″ | schema:familyName | Laviola |
184 | ″ | schema:givenName | Luigi |
185 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354727540.43 |
186 | ″ | rdf:type | schema:Person |
187 | sg:person.0706015255.97 | schema:affiliation | grid-institutes:None |
188 | ″ | schema:familyName | Di Bartolo |
189 | ″ | schema:givenName | Paolo |
190 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706015255.97 |
191 | ″ | rdf:type | schema:Person |
192 | sg:pub.10.1007/s12325-018-0868-9 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1111099911 |
193 | ″ | ″ | https://doi.org/10.1007/s12325-018-0868-9 |
194 | ″ | rdf:type | schema:CreativeWork |
195 | sg:pub.10.1007/s13300-015-0142-y | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1048653953 |
196 | ″ | ″ | https://doi.org/10.1007/s13300-015-0142-y |
197 | ″ | rdf:type | schema:CreativeWork |
198 | sg:pub.10.1007/s13300-018-0452-y | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1104347182 |
199 | ″ | ″ | https://doi.org/10.1007/s13300-018-0452-y |
200 | ″ | rdf:type | schema:CreativeWork |
201 | sg:pub.10.1007/s13300-019-00715-x | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1122193928 |
202 | ″ | ″ | https://doi.org/10.1007/s13300-019-00715-x |
203 | ″ | rdf:type | schema:CreativeWork |
204 | sg:pub.10.1007/s13300-019-00725-9 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1123157757 |
205 | ″ | ″ | https://doi.org/10.1007/s13300-019-00725-9 |
206 | ″ | rdf:type | schema:CreativeWork |
207 | sg:pub.10.1007/s13300-019-00735-7 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1123468257 |
208 | ″ | ″ | https://doi.org/10.1007/s13300-019-00735-7 |
209 | ″ | rdf:type | schema:CreativeWork |
210 | sg:pub.10.1007/s13300-019-0624-4 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1113668568 |
211 | ″ | ″ | https://doi.org/10.1007/s13300-019-0624-4 |
212 | ″ | rdf:type | schema:CreativeWork |
213 | grid-institutes:None | schema:alternateName | Diabetes Center District 3, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy |
214 | ″ | ″ | Diabetes Unit, SSD Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy |
215 | ″ | ″ | Ravenna Diabetes Clinic, Romagna Local Health Authority, Ravenna, Italy |
216 | ″ | schema:name | Diabetes Center District 3, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy |
217 | ″ | ″ | Diabetes Unit, SSD Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy |
218 | ″ | ″ | Ravenna Diabetes Clinic, Romagna Local Health Authority, Ravenna, Italy |
219 | ″ | rdf:type | schema:Organization |
220 | grid-institutes:grid.412451.7 | schema:alternateName | Department of Medicine and Aging Sciences (DMSI) and Center for Research on Ageing and Translational Medicine (CeSI-Met), University of Chieti, Chieti, Italy |
221 | ″ | schema:name | Department of Medicine and Aging Sciences (DMSI) and Center for Research on Ageing and Translational Medicine (CeSI-Met), University of Chieti, Chieti, Italy |
222 | ″ | rdf:type | schema:Organization |
223 | grid-institutes:grid.5608.b | schema:alternateName | Division of Metabolic Diseases, Department of Medicine, University of Padova, Padua, Italy |
224 | ″ | schema:name | Division of Metabolic Diseases, Department of Medicine, University of Padova, Padua, Italy |
225 | ″ | rdf:type | schema:Organization |
226 | grid-institutes:grid.7644.1 | schema:alternateName | Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Transplants, University of Bari Aldo Moro, Bari, Italy |
227 | ″ | schema:name | Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Transplants, University of Bari Aldo Moro, Bari, Italy |
228 | ″ | rdf:type | schema:Organization |